Search Within

Andrew D Zelenetz

  1. "Epidemiology and Biostatistics"
Formats
  1. Meeting Abstract (79)
  2. Journal Article (72)
  3. Research Letter (2)
Groups
  1. Center for Hematologic Malignancies (153)
  2. Department of Medicine (153)
  3. Epidemiology and Biostatistics (153)
  4. Hematologic Malignancies, Division of (153)
  5. Lymphoma (153)
  6. Biostatistics Service (127)

More Groups

People
  1. Paul Hamlin (75)
  2. Craig Moskowitz (74)
  3. Anita Kumar (68)
  4. Ariela Noy (67)
  5. Maria Palomba (64)
  6. David Straus (63)

More People

Years
  1. 2025 (3)
  2. 2024 (5)
  3. 2023 (12)
  4. 2022 (9)
  5. 2021 (15)
  6. 2020 (9)

More Years

Publications
  1. Blood (64)
  2. Journal of Clinical Oncology (17)
  3. Hematological Oncology (11)
  4. Blood Advances (8)
  5. British Journal of Haematology (8)
  6. Haematologica (6)

More Publications

Publishers
  1. American Society of Hematology (72)
  2. American Society of Clinical Oncology (17)
  3. Wiley Blackwell (11)
  4. Nature Publishing Group (9)
  5. John Wiley & Sons (8)
  6. Elsevier Inc. (7)

More Publishers

Results (153)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: A retrospective, pooled cohort study with external validations
    Journal Article

    Soumerai, J. D.; Ni, A.; Darif, M.; Londhe, A.; Xing, G.; Mun, Y.; Kay, N. E.; Shanafelt, T. D.; Rabe, K. G.; Byrd, J. C.; more...
    The Lancet Haematology (2019)

    Fulltext@MSK | Save
  • Incidence and treatment outcomes of patients with transformed marginal zone lymphoma treated with RCHOP‐like regimens
    Meeting Abstract

    Rajeeve, S.; Bobillo, S. V.; Zelenetz, A. D.; Straus, D. J.; Palomba, M. L.; Noy, A.; Horwitz, S. M.; Moskowitz, A. J.; Hamlin, P. A.; Matasar, M. J.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of stage I diffuse large B cell lymphoma (DLBCL) in the rituximab‐era
    Meeting Abstract

    Bobillo, S.; Joffe, E.; Lavery, J.; Noy, A.; Palomba, L.; Straus, D. J.; Kumar, A.; Batlevi, C.; Horwitz, S.; Moskowitz, A.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Impact of pet imaging and histologic transformation on the prognosis of early disease progression in follicular lymphoma
    Meeting Abstract

    Batlevi, C. L.; Sha, F.; Alperovich, A.; Ni, A.; Smith, K.; Ying, Z.; Hamlin, P.; Horwitz, S. M.; Kumar, A.; Matasar, M.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: Progressive shortening in response duration and survival after each relapse
    Journal Article

    Kumar, A.; Sha, F.; Toure, A.; Dogan, A.; Ni, A.; Batlevi, C. L.; Palomba, M. L. M.; Portlock, C.; Straus, D. J.; Noy, A.; more...
    Blood Cancer Journal (2019)

    Fulltext@MSK | Save
  • Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma
    Journal Article

    Kumar, A.; Ying, Z.; Alperovich, A.; Dogan, A.; Hamlin, P.; Moskowitz, C.; Pichardo, J.; Portlock, C.; Sha, F.; Zelenetz, A. D.; more...
    Haematologica (2019)

    Fulltext@MSK | Save
  • Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia
    Journal Article

    Leeksma, A. C.; Taylor, J.; Wu, B.; Gardner, J. R.; He, J.; Nahas, M.; Gonen, M.; Alemayehu, W. G.; te Raa, D.; Walther, T.; more...
    Leukemia (2019)

    Fulltext@MSK | Save
  • Preliminary safety and efficacy results with an intermittent schedule of the PI3kδ inhibitor ME-401 alone or in combination with rituximab for B-cell malignancies
    Meeting Abstract

    Zelenetz, A. D.; Soumerai, J. D.; Jagadeesh, D.; Reddy, N.; Stathis, A.; Asch, A. S.; Salman, H. S.; Kenkre, V. P.; Jhangiani, H.; Iasonos, A.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Risk model for overall survival for patients with relapsed/refractory chronic lymphocytic leukemia: Validated for patients on ibrutinib, idelalisib, venetoclax, or chemoimmuniotheraphy
    Meeting Abstract

    Soumerai, J. D.; Ni, A.; Darif, M.; Londhe, A.; Xing, G.; Mun, Y.; Kay, N. E.; Shanafelt, T. D.; Chaffee, K. G.; Furman, R. R.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Initial results of a dose escalation study of a selective and structurally differentiated PI3Kδ inhibitor, ME-401, in relapsed/refractory (R/R) follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
    Meeting Abstract

    Soumerai, J. D.; Pagel, J. M.; Jagadeesh, D.; Salman, H. S.; Kenkre, V. P.; Asch, A. S.; Stathis, A.; Reddy, N. M.; Iasonos, A.; Ghalie, R.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save